News >

Expert Discusses Promise of Checkpoint Inhibitors in Ovarian Cancer

Angelica Welch
Published: Tuesday, Nov 21, 2017

What I would say to oncologists in the community would be to try to get your patients into a clinical trial so that they can be studied in an environment where they can gain information as they gain benefit from the treatment. 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication